Biocept FGFR1 Blood Test
Biocept has launched blood-based FGFR1 amplification testing as a tool that doctors can use to discern which patients might benefit from certain breast and lung cancer therapies. Studies have implicated FGFR1 amplification as a driver of breast, non-small cell, and small cell lung cancers, and clinical trials are investigating treatments targeting this pathway.
FGFR1 testing is part of Biocept's portfolio of liquid biopsy tests for monitoring disease resistance and personalizing treatments for patients who don't have enough tissue from tumor biopsies. The molecular diagnostic firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma. Biocept markets OncoCEE-GA for gastric cancer, OncoCEE-BR for breast cancer and OncoCEE-LU for non-small cell lung cancer.